

MEDICAL POLICY

POLICY TITLE	TRIGGER POINT AND TENDER POINT INJECTIONS
POLICY NUMBER	MP-2.072

Original Issue Date (Created):	3/8/2004
Most Recent Review Date (Revised):	4/29/2020
Effective Date:	07/01/2020

[POLICY RATIONALE](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)
[BENEFIT VARIATIONS](#)
[REFERENCES](#)

I. POLICY

Trigger and tender point injections with anesthetic and/or corticosteroid may be considered **medically necessary** for the treatment of chronic neck or back pain, myofascial pain syndrome, or fibromyalgia when all of the following criteria have been met:

- There is a regional pain complaint in the expected distribution of referral pain from a trigger point, AND
- There is spot tenderness in a palpable taut band in a muscle, AND
- There is restricted range of motion, AND
- Conservative therapy (e.g., physical therapy, active exercises, ultrasound, heating or cooling, massage, activity modification, or pharmacotherapy) for 6 weeks fails or is not feasible, AND
- Trigger point injections are provided as a component of a comprehensive therapy program, AND
- No more than 4 injections are given in a 12-month period

Trigger point and tender point injections are considered **investigational** for all other indications not meeting the criteria above. There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

Ultrasound and other imaging guidance of trigger point injections is considered **investigational** as there is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

Cross-reference:

- MP-3.015** Office Based Procedures Performed in a Facility
- MP-4.014** Epidural Steroid Injections for Back Pain and Facet Nerve Blocks
- MP-4.041** Dry Needling of Myofascial Trigger Points

MEDICAL POLICY

POLICY TITLE	TRIGGER POINT AND TENDER POINT INJECTIONS
POLICY NUMBER	MP-2.072

II. PRODUCT VARIATIONS

[Top](#)

This policy is only applicable to certain programs and products administered by Capital BlueCross and subject to benefit variations as discussed in Section VI. Please see additional information below.

FEP PPO - The FEP program dictates that all drugs, devices or biological products approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational. Therefore, FDA-approved drugs, devices or biological products may be assessed on the basis of medical necessity.

III. DESCRIPTION/BACKGROUND

[Top](#)

TRIGGER POINTS

Trigger points are discrete, focal, hyperirritable spots within a taut band of skeletal muscle fibers that produce local and/or referred pain when stimulated. Trigger points are associated with local ischemia and hypoxia, a significantly lowered pH, local and referred pain, and altered muscle activation patterns.

Trigger point injections with local anesthetic, saline, steroid, or botulinum toxin type A are a potential treatment for pain associated with trigger points. Alternative nonpharmacologic treatment modalities for trigger point pain include manual techniques, massage, acupressure, ultrasonography, application of heat or ice, diathermy, transcutaneous electrical nerve stimulation, and spray cooling with manual stretch.

TENDER POINTS

Tender points are focal areas of hyperalgesia that tend to occur at muscle tendon junctions. Tender points are differentiated from trigger points due to the absence of a taut band of muscle tissue or local hyperirritability (“jump response”) when palpated.

Despite the lack of local hyperirritability or a palpable band of tissue, some practitioners have treated tender points with injections of local anesthetic, corticosteroids, or botulinum toxin, similar to the treatment of trigger points.

Associated Disorders

Myofascial Pain Syndrome

Myofascial pain syndrome is a chronic regional pain disorder caused by the activation of at least 1 trigger point in muscles, tendons, or muscle fascia. It can cause local or referred pain, tightness, tenderness, stiffness and limitation of movement, muscle weakness, and often autonomic phenomena. The severity of symptoms and degree of functional impairment vary. Some individuals will have few trigger points with mild symptoms and no functional impairment, while others will have multiple satellite trigger points, widespread and severe pain, and major functional impairments. Conditions that can lead to myofascial pain syndrome include chronic repetitive

MEDICAL POLICY

POLICY TITLE	TRIGGER POINT AND TENDER POINT INJECTIONS
POLICY NUMBER	MP-2.072

minor muscle strain, poor posture, systemic disease, strain, sprain, enthesopathy, and arthritis. Management of chronic myofascial pain typically includes behavioral and pharmacologic approaches and physical therapy. Injection of a local anesthetic or botulinum toxin has also been reported.

Complex Regional Pain Syndrome

Complex regional pain syndrome (CRPS; previously called sympathetic dystrophy) refers to a chronic and disabling condition characterized by persistent pain that is disproportionate to the extent and duration of the primary injury and that is not restricted to the distribution of a specific peripheral nerve. CRPS occurs most commonly following wrist fracture, but may follow many other types of injury, even when the preceding injury is relatively minor. CRPS may also occur when there is no known injury. CRPS is classified into type I when a specific nerve lesion has not been identified and type II when there is an identifiable nerve lesion. The pain may consist of thermal or mechanical allodynia (pain that occurs from a stimulus that normally does not elicit a painful response such as light touch or warmth) dysesthesia (a constant or ongoing unpleasant or electrical sensation of pain), and/or hyperalgesia (an exaggerated response to normally painful stimuli). Management of CRPS includes oral and topical pharmacotherapy, physical therapy, psychological therapies, and interventional procedures such as regional anesthetic blocks, sympathetic blocks, or spinal cord stimulation. Amputation of the affected limb has also been performed.

Abdominal Wall Pain

A source of chronic abdominal wall pain is anterior cutaneous nerve entrapment syndrome, which typically presents as sharp and focal abdominal pain, and is often found near a scar. One hypothesis is that anterior cutaneous nerve entrapment syndrome results from the entrapment and ischemia of an anterior cutaneous branch of a thoracic nerve as it passes through the rectus abdominus muscle. Anterior wall pain can be distinguished from intra-abdominal pain by documenting that pain increases with maneuvers that tense the abdominal muscles. It has also been proposed that abdominal wall pain may be due to a myofascial trigger point in the rectus abdominus muscle.

Fibromyalgia

Fibromyalgia is a chronic condition characterized by widespread pain with hyperalgesia and allodynia. Constitutional symptoms such as fatigue, impaired cognition, and disrupted sleep can also occur. Early diagnostic criteria for fibromyalgia (1990) included three or more months of widespread pain above and below the waist, on both sides of the body, and along the midline, with at least 11 of 18 specific tender points. The defined bilateral areas from the American College of Rheumatology (ACR) criteria are occipital, low cervical, trapezius, supraspinatus, second rib, lateral epicondyle, gluteal, greater trochanter, and knee medial fat pad. However, 2010 diagnostic criteria from ACR, which were designed to facilitate diagnosis in a general practice setting, did not include a tender point exam but instead relied on the presence of widespread pain and other symptoms.

MEDICAL POLICY

POLICY TITLE	TRIGGER POINT AND TENDER POINT INJECTIONS
POLICY NUMBER	MP-2.072

REGULATORY STATUS

Although medications used with invasive trigger point and tender point procedures are regulated by the U.S. Food and Drug Administration (FDA), trigger and tender point injections are procedures and, as such, are not subject to regulation by the Food and Drug Administration.

IV. RATIONALE

[Top](#)

SUMMARY OF EVIDENCE

For individuals who have myofascial pain syndrome who receive trigger point injections, the evidence includes several randomized controlled trials (RCTs) and a systematic review of RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Lidocaine injections have been compared to physical therapy, lidocaine patches, sham stimulation, and dry needling. Some trials have reported that injecting lidocaine into trigger points improve subjective pain ratings to the same degree as physical therapy or lidocaine patches, but only slightly more than sham stimulation. Other trials have found that lidocaine injection was superior to dry needling on subjective pain ratings, but there was no significant benefit with lidocaine injection assessed on objective outcome measures. These results suggest a strong placebo effect of the treatment. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have complex regional pain syndrome who receive trigger point injections, the evidence includes case series. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Evidence on treatment of complex regional pain syndrome with trigger point injections is very limited, with only case series published and no recent literature identified for this treatment approach. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have abdominal wall pain who receive trigger point injections, the evidence includes one RCT. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The single RCT evaluated lidocaine injections in women who had chronic pelvic pain and abdominal wall trigger points. Additional study in a larger population is needed to permit greater certainty about the efficacy of this treatment approach. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have fibromyalgia who receive tender point injections, the evidence includes one RCT. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The single RCT identified evaluated the efficacy of lidocaine injections in patients with fibromyalgia. It found a strong placebo effect, with lidocaine injection being not more effective than saline at reducing fibromyalgia pain.

MEDICAL POLICY

POLICY TITLE	TRIGGER POINT AND TENDER POINT INJECTIONS
POLICY NUMBER	MP-2.072

V. DEFINITIONS

[Top](#)

N/A

VI. BENEFIT VARIATIONS

[Top](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits and which require preauthorization. There are different benefit plan designs in each product administered by Capital BlueCross. Members and providers should consult the member's health benefit plan for information or contact Capital BlueCross for benefit information.

VII. DISCLAIMER

[Top](#)

Capital BlueCross's medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital BlueCross' Provider Services or Member Services. Capital BlueCross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

[Top](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Ultrasound and other imaging guidance of trigger point injections is considered investigational; therefore, not covered:

CPT Code®							
76942	77002	77021					

Current Procedural Terminology (CPT) copyrighted by American Medical Association. All Rights Reserved.

MEDICAL POLICY

POLICY TITLE	TRIGGER POINT AND TENDER POINT INJECTIONS
POLICY NUMBER	MP-2.072

A maximum of four (4) injections within a 12-month period are covered when medically necessary:

CPT Codes®							
20552	20553						

Current Procedural Terminology (CPT) copyrighted by American Medical Association. All Rights Reserved.

ICD-10-CM Diagnosis Code	Description
G89.29	Other Chronic Syndrome
G89.4	Chronic Pain Syndrome
M54.2	Cervicalgia
M54.5	Low Back Pain
M79.10	Myalgia, unspecified site
M79.12	Myalgia of auxiliary muscles, head and neck
M79.18	Myalgia, other site
M79.7	Fibromyalgia

IX. REFERENCES

[Top](#)

1. American Physical Therapy Association (APTA). *Description of Dry Needling in Clinical Practice: An Educational Resource Paper*. 2013; <http://www.apta.org/StateIssues/DryNeedling/ClinicalPracticeResourcePaper/>. Accessed April 29, 2020.
2. Alvarez DJ, Rockwell PG. Trigger points: diagnosis and management. *Am Fam Physician*. Feb 15 2002;65(4):653-660. PMID 11871683
3. O'Connell NE, Wand BM, McAuley J, et al. Interventions for treating pain and disability in adults with complex regional pain syndrome. *Cochrane Database Syst Rev*. Apr 30 2013;4(4):CD009416. PMID 23633371
4. Alnahhas MF, Oxentenko SC, Locke GR, 3rd, et al. Outcomes of ultrasound-guided trigger point injection for abdominal wall pain. *Dig Dis Sci*. Feb 2016;61(2):572-577. PMID 26320087
5. Sumpton JE, Moulin DE. Fibromyalgia. *Handb Clin Neurol*. Dec 2014;119:513-527. PMID 24365316
6. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. *Arthritis Care Res (Hoboken)*. May 2010;62(5):600-610. PMID 20461783
7. Lugo LH, Garcia HI, Rogers HL, et al. Treatment of myofascial pain syndrome with lidocaine injection and physical therapy, alone or in combination: a single blind, randomized, controlled clinical trial. *BMC Musculoskelet Disord*. Feb 24 2016;17(1):101. PMID 26911981

POLICY TITLE	TRIGGER POINT AND TENDER POINT INJECTIONS
POLICY NUMBER	MP-2.072

8. *Affaitati G, Fabrizio A, Savini A, et al. A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds. Clin Ther. Apr 2009;31(4):705-720. PMID 19446144*
9. *Couto C, de Souza IC, Torres IL, et al. Paraspinal stimulation combined with trigger point needling and needle rotation for the treatment of myofascial pain: a randomized sham-controlled clinical trial. Clin J Pain. Mar 2014;30(3):214-223. PMID 23629597*
10. *Hong CZ. Lidocaine injection versus dry needling to myofascial trigger point. The importance of the local twitch response. Am J Phys Med Rehabil. Jul-Aug 1994;73(4):256-263. PMID 8043247*
11. *Brennan KL, Allen BC, Maldonado YM. Dry needling versus cortisone injection in the treatment of greater trochanteric pain syndrome: a noninferiority randomized clinical trial. J Orthop Sports Phys Ther. Apr 2017;47(4):232-239. PMID 28257614*
12. *Hong CZ. Specific sequential myofascial trigger point therapy in the treatment of a patient with myofascial pain syndrome associated with reflex sympathetic dystrophy. Australas Chiropr Osteopathy. Mar 2000;9(1):7-11. PMID 17987165*
13. *Dunn DG. Chronic regional pain syndrome, type 1: Part II. AORN J. Oct 2000;72(4):643-651, 653; quiz 654, 656-648, 661-642. PMID 11076283*
14. *Oor JE, Unlu C, Hazebroek EJ. A systematic review of the treatment for abdominal cutaneous nerve entrapment syndrome. Am J Surg. Jul 2016;212(1):165-174. PMID 26945611*
15. *Montenegro ML, Braz CA, Rosa-e-Silva JC, et al. Anaesthetic injection versus ischemic compression for the pain relief of abdominal wall trigger points in women with chronic pelvic pain. BMC Anesthesiol. Dec 1 2015;15:175. PMID 26628263*
16. *Staud R, Weyl EE, Bartley E, et al. Analgesic and anti-hyperalgesic effects of muscle injections with lidocaine or saline in patients with fibromyalgia syndrome. Eur J Pain. Jul 2014;18(6):803-812. PMID 24193993*
17. *American Society of Anesthesiologists Task Force on Chronic Pain Management, American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. Apr 2010;112(4):810-833. PMID 20124882*
18. *Novitas Solutions Inc. Local Coverage Determination (LCD): Trigger Point Injections (L35010). Effective 3/8/18 ; https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=35010&ver=17&Date=10%2f17%2f2018&SearchType=Advanced&DocID=L35010&search_id=&service_date=&bc=KAAAABgAAAA& Accessed April 29, 2020.*
19. *Blue Cross Blue Shield Association Medical Policy Reference Manual. 2.01.103, Trigger Point and Tender Point Injections. April 2019.*

MEDICAL POLICY

POLICY TITLE	TRIGGER POINT AND TENDER POINT INJECTIONS
POLICY NUMBER	MP-2.072

Additional references for chronic neck and back pain and fibromyalgia

1. Hong CZ, Hsueh TC. Difference in pain relief after trigger point injections in myofascial pain patients with and without fibromyalgia. *Arch Phys Med Rehabil.* 1996;77(11):1161-1166.
2. Scott A, Guo B. Trigger Point Injections for Chronic Non-Malignant Musculoskeletal Pain Health Technology Assessment (HTA) number 35. Alberta Heritage Foundation for Medical Research. 2005.
3. Staal JB, de Bie R, de Vet HCW, et al. Injection therapy for subacute and chronic low-back pain. *Cochrane Database Syst Rev.* 2008, 3):CD001824.
4. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. *Arthritis Care Res (Hoboken).* 2010; 62(5):600-610.

X. POLICY HISTORY

[Top](#)

MP 2.072	CAC 1/31/17 Policy criteria were previously addressed in MP-4.014 Pain Control. BCBSA policy adopted. Trigger and tender point injections are considered medically necessary for myofascial pain under specified conditions. Coding added.
	1/1/18 Admin Update: Medicare variations removed from Commercial Policies.
	1/12/18 Minor review. Policy statement updated to state that imaging in addition to ultrasound is considered investigational. Coding reviewed
	10/1/18 Admin Update: Removed deleted ICD-10 codes. Added new ICD-10 codes effective 10/1/18
	10/17/18 Consensus review. No change to policy statements. References updated. Rationale condensed.
	5/24/19 Minor review. Added chronic neck and back pain as well as fibromyalgia as medically necessary indications. Updated references and coding.
	4/29/2020: Consensus Review. No change to policy statement. References checked and updated. Coding reviewed with no changes.

[Top](#)

Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies.